| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 1/2a data readout example | AMT-191 (investigational gene therapy) Fabry disease | Phase 1/2a | — | Gene Therapies | Rare Diseases | ||
phase 1/2a data readout example | AMT-191 (investigational gene therapy) Fabry disease | Phase 1/2a | — | Gene Therapies | Rare Diseases | ||
phase 1/2a data readout example | AMT-191 (investigational gene therapy) Fabry disease | Phase 1/2a | — | Gene Therapies | Rare Diseases |
Recent Updates
Recently added Catalysts
uniQure N.V.$46.29
-1.87 (-3.88%)
D 32Pipeline Score Richly Valued Biotech · Commercial
Market Cap
1.51 B
EPS
-3.51
P/E Ratio
-
Value Trade
84.91 M
SEC Financials
Q1 2026Dilution Risk
40%Revenue
3.56 M
R&D Expenses
29.18 M
Operating CF
-38.24 M
Total Assets
778.71 M
Total Liabilities
629.36 M
Equity
149.34 M
D/E Ratio
12,345
-11.72 %
Week
36.59 %
1 Month
1.38 %
3 Month
-12.92 %
6 Month
-30.15 %
5 Year
42.29 %
All Time
Cash Data
Cash Position
141.54 M
Monthly Burn
12.75 M
Runway
9.7 mo
Burn Trend
StableSEC Filing
May 5, 2026
Overview
Volume
4.86 M
52 Week Range
8.73 - 71.50
% held by Insiders
9.53 %
% held by Institutions
90.07 %
Enterprise Value
1.47 B
Total Shares
62.51 M
Short %
19.86 %
Float Shares
55.88 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D32
Pipeline Score $49M
Pipeline ValueRichly Valued
Valuation Signal3
Drugs Scored0.0x
rNPV / MCap Top 40%
Micro Cap (rank 544 of 905)
Percentile RankuniQure N.V. faces pipeline headwinds (32/100), with $192M risk-adjusted pipeline value, led by rAAV2/5-PBGD vector dosage 1 in Acute Intermittent Porphyria (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| rAAV2/5-PBGD vector dosage 1 Gene therapy | Acute Intermittent Porphyria | Phase 1 | NCT02082860 | 19% | $127M | COMPLETED | 8 | - | - | Nov 1, 2014 | - | Dec 18, 2014 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
AMT-260 | refractory mesial temporal lobe epilepsy | Phase 1/2 | 2025-07-30 | |||
AMT-260 | refractory mesial temporal lobe epilepsy | Phase 1/2 | 2025-07-30 | |||
AMT-260 | refractory mesial temporal lobe epilepsy | Phase 1/2 | 2025-07-30 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in QURE
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
QURE
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
QURE
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
QURE
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
QURE Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
QURE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
QUREuniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy
uniQure has announced preliminary data from its Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy. The initial results show that three out of six patients experienced significant reductions in seizures, while the remaining patients had variable responses. The treatment was well-tolerated with no serious adverse events reported, supporting further evaluation of AMT-260.
Read more →QUREuniQure Announces Plan for BLA Submission for AMT-130 in Huntington’s Disease
uniQure announced plans to submit a Biologics License Application (BLA) for AMT-130, a gene therapy for Huntington's disease, based on a 3-year analysis from its Phase I/II study. The FDA has indicated this data is acceptable for accelerated approval. The company aims to submit the BLA by Q3 2026 and is aligning on the confirmatory study design with the FDA.
Read more →QUREuniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates
uniQure reported its Q1 2026 financial results, highlighting advancements in its gene therapy pipeline, particularly AMT-130 for Huntington's disease and AMT-191 for Fabry disease. The company has scheduled a Type B meeting with the FDA and expects to submit a Marketing Authorization Application in the UK. Despite a strong cash position, the company faces challenges with regulatory feedback and safety concerns in ongoing trials.
Read more →QUREuniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington’s Disease
uniQure announced a successful Pre-Submission Meeting with the UK's MHRA regarding AMT-130 for Huntington's disease. The company plans to submit a Marketing Authorization Application in Q3 2026, supported by promising trial data showing a 75% slowing of disease progression. Additionally, a Type B meeting with the U.S. FDA is scheduled to discuss Phase III trial design.
Read more →QUREuniQure to Announce First Quarter 2026 Financial Results
uniQure N.V. will announce its first quarter 2026 financial results on May 5, 2026. The company will host a conference call at 8:30 a.m. ET to discuss these results. The event will be available via webcast, and a replay will be accessible for 90 days. Analysts can join the call by dialing in with a specific conference ID.
Read more →QUREuniQure Announces 2025 Financial Results and Provides Recent Company Updates
uniQure reported its 2025 financial results and highlighted advancements in its gene therapy programs. The company is evaluating Phase III development for AMT-130, which has shown significant efficacy in Huntington's disease. Additionally, AMT-260 and AMT-191 are progressing with promising early data. However, regulatory challenges remain, particularly with the FDA's recommendations for AMT-130.
Read more →QUREuniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
uniQure announced a regulatory update regarding AMT-130, its investigational gene therapy for Huntington's disease. The FDA indicated that the existing Phase I/II data is insufficient for a marketing application and recommended a new randomized study. uniQure plans to continue discussions with the FDA and request a Type B meeting to explore potential study designs.
Read more →QUREuniQure to Announce 2025 Financial Results
uniQure N.V. will announce its fourth quarter and full year 2025 financial results on March 2, 2026. Following the announcement, a conference call will be held at 8:00 a.m. ET, accessible via a live webcast. Analysts can participate in a Q&A session by calling in with a provided conference ID.
Read more →QUREuniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
uniQure has released updated preliminary data from its Phase I/IIa trial of AMT-191 for Fabry disease, showing sustained increases in α-Gal A enzyme activity in all patients. Six out of eleven patients have successfully discontinued enzyme replacement therapy. The therapy demonstrated a manageable safety profile, although some patients experienced liver enzyme elevations, leading to a pause in higher dose cohorts for further assessment.
Read more →QUREuniQure Announces Type A Meeting Scheduled with FDA
uniQure has announced a Type A meeting with the FDA to discuss the Biologics License Application for AMT-130, a gene therapy aimed at treating Huntington's disease. The company emphasizes the urgent need for effective therapies in this area and is committed to working closely with the FDA. A regulatory update will follow after the meeting.
Read more →QUREData Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years
The five-year results from the Phase 3 HOPE-B study confirm the long-term durability and safety of HEMGENIX (etranacogene dezaparvovec-drlb) for adults with hemophilia B. Published in the NEJM, the data show sustained therapeutic benefits, including a 94% rate of freedom from prophylaxis treatment and strong factor IX activity levels. HEMGENIX remains the only gene therapy available for this condition.
Read more →QUREuniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update
uniQure reported its Q3 2025 financial results, highlighting significant progress in its clinical programs, particularly with AMT-130 for Huntington's disease, which met key endpoints. The company also received unexpected feedback from the FDA regarding its BLA submission, prompting a need for urgent discussions. Financially, uniQure raised $323.7 million, enhancing its cash reserves to $694.2 million.
Read more →QUREuniQure to Announce Third Quarter 2025 Financial Results
uniQure N.V. will announce its third quarter 2025 financial results on November 10, 2025, before market open. Following the announcement, a conference call will be held at 8:30 a.m. ET, which will also be available via webcast. Analysts can participate in the Q&A session by calling in with a passcode.
Read more →QUREuniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
uniQure N.V. has successfully closed an upsized public offering, selling 6,736,841 ordinary shares at $47.50 each, raising around $345 million. The offering included additional shares purchased by underwriters and pre-funded warrants. The funds will support commercialization readiness for AMT-130 and other clinical developments. The offering was managed by several financial institutions.
Read more →QUREuniQure Announces Pricing of Upsized $300 Million Public Offering
uniQure N.V. has announced the pricing of its public offering of 5,789,473 ordinary shares at $47.50 each, aiming to raise around $300 million. The offering is set to close on or about September 29, 2025, pending customary conditions. The company continues to advance its gene therapy pipeline for various severe diseases.
Read more →QUREuniQure Announces $200 Million Proposed Public Offering
uniQure N.V. has announced a proposed public offering of $200 million in ordinary shares and pre-funded warrants. The offering is underwritten and includes a 30-day option for underwriters to purchase additional shares. The completion of the offering is subject to market conditions, and the final terms will be disclosed in a prospectus supplement.
Read more →QUREuniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding
uniQure N.V. has announced a $175 million non-dilutive senior secured term loan facility with Hercules Capital. This refinancing extends the term of existing debt to October 2030 and provides access to additional funds to support the potential commercial launch of AMT-130 for Huntington's disease. The transaction aims to enhance the company's financial flexibility and reduce capital costs.
Read more →QUREuniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease
uniQure announced positive topline results from its pivotal Phase I/II study of AMT-130 for Huntington's disease. The study met its primary endpoint, showing a significant 75% slowing of disease progression at 36 months. Additionally, AMT-130 demonstrated favorable trends in secondary endpoints and was well-tolerated. The company plans to submit a Biologics License Application in early 2026.
Read more →QUREuniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
uniQure has announced promising initial data from its Phase I/IIa trial of AMT-191 for Fabry disease, showing significant increases in α-Gal A enzyme activity among all patients in the first cohort. All patients were able to discontinue enzyme replacement therapy, indicating the potential effectiveness of AMT-191. The treatment exhibited a manageable safety profile, with further results expected in 2026.
Read more →Competitive Position
How QURE ranks across every disease it competes inCompetitive Position is a premium feature
See how QURE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial